Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 131, Issue 1, 2007, Pages 76-80

  Kodama, Junichi ^a   Seki, Noriko ^a   Ojima, Yojiro ^a   Nakamura, Keiichiro ^a   Hongo, Atsushi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Endometrial cancer; Histologic grade; Prognostic factor; Surgical staging

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; PIRARUBICIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HYSTERECTOMY; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

EID: 33847137283     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.01.006     Document Type: Article

References (16)

1. Berek J.S., Adashi E.Y., and Hillard P.A. Novaks GYNECOLOGY (1996), Williams & Wilkins Inc., Maryland p. 1057-1110
2. Announcements: FIGO stages-1988 revision. Gynecol Oncol 35 (1989) 125-127
3. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
4. Aalders J., Abeler V., Kolstad P., and Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56 (1980) 419-427
5. Creutzberg C.L., van Putten W.L.J., Koper P.C.M., et al. Surgery and post-operative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. Lancet 355 (2000) 1401-1411
6. Naumann R.W., Higgins R.V., and Hall J.B. The use of adjuvant radiation therapy by members of the Society Gynecologic Oncologists. Gynecol Oncol 75 (1999) 4-9
7. Jolly S., Vargas C., Kumar T., et al. Vaginal brachytherapy alone: An alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol 97 (2005) 887-892
8. Hirai M., Hirono M., Oosaki T., Hayashi T., Yoshihara T., and Itami M. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. Int J Gynecol Oncol 78 (2002) 37-44
9. Aoki Y., Watanabe M., Amikura T., et al. Adjuvant chemotherapy as treatment of high-risk stag I and II endometrial cancer. Gynecol Oncol 94 (2004) 333-339
10. Kasamatsu T., Onda T., Katsumata N., et al. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. Br J cancer 88 (2003) 245-250
11. Ayhan A., Taskiran C., Celik C., and Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol 93 (2004) 9-13
12. Tebeu P.-M., Popowski Y., Verkooijen H.M., et al. Positive peritoneal cytology in early-stage endometrial cancer dose not influence prognosis. Br J Cancer 91 (2004) 720-724
13. Look K. Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation. Int J Gynecol Cancer 12 (2002) 237-249
14. Sartori E., Laface B., Gadducci A., et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Force (CTF) study. Int J Gynecol Cancer 13 (2003) 458-465
15. Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., and Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 95 (2004) 593-596
16. Randall M.E., Brunetto G., Muss H., et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the gynecologic oncology. Proc Am Soc Clin Oncol 22 (2003) 22 [Abstract 3]